140 related articles for article (PubMed ID: 1919625)
1. Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Jones SE; Mennel RG; Brooks B; Westrick MA; Allison MA; Paulson RS; Tilmann K; Rea B
J Clin Oncol; 1991 Oct; 9(10):1736-9. PubMed ID: 1919625
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
Hainsworth JD; Andrews MB; Johnson DH; Greco FA
J Clin Oncol; 1991 Oct; 9(10):1731-5. PubMed ID: 1919624
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.
Hainsworth JD; Jones SE; Mennel RG; Blum JL; Greco FA
J Clin Oncol; 1996 May; 14(5):1611-6. PubMed ID: 8622079
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
7. The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
Hainsworth JD
Ann Oncol; 1993; 4 Suppl 2():37-40. PubMed ID: 7688982
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer.
Repetto L; Miglietta L; Gardin G; Lanfranco C; Naso C; Merlini L; Giudici S; Venturino A; Campora E; Testore F
Breast Cancer Res Treat; 1994; 30(2):133-7. PubMed ID: 7949211
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L
Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
12. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
13. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM
Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective and well-tolerated regimen for the treatment of advanced breast cancer.
Wils JA
Eur J Cancer; 1993; 29A(15):2106-8. PubMed ID: 8297648
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Klaassen U; Harstrick A; Wilke H; Seeber S
Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
[TBL] [Abstract][Full Text] [Related]
16. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.
Margolin KA; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Raschko JW; Somlo G; Blevins C
J Clin Oncol; 1992 Aug; 10(8):1278-83. PubMed ID: 1634917
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
Bascioni R; Giorgi F; Silva RR; Acito L; Giustini L; De Signoribus G; Giuliodori L; Testa E
Breast Cancer Res Treat; 1997 Sep; 45(3):205-10. PubMed ID: 9386863
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Aitini E; Cavazzini G; Cantore M; Rabbi C; Rivera A; Togliani B; Di Marco A; Smerieri F
Eur J Cancer; 1992; 28A(12):1968-70. PubMed ID: 1419291
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: a phase II study.
Susnjar S; Vasović S; Nesković-Konstantinović Z; Stamatović L; Lukić V; Colaković S; Mitrovic L; Jelić S; Radulović S
Tumori; 1999; 85(6):478-82. PubMed ID: 10774569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
